Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Rosner S, Reuss JE, Zahurak M, Zhang J, et al. Clin Cancer Res 2023 Feb 15:OF1-OF6. doi: 10.1158/1078-0432.CCR-22-2994.

Read + Share

Amedeo Smart

Independent Medical Education

Rosner S, Reuss JE, Zahurak M, Zhang J, et al. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 2023 Feb 15:OF1-OF6. doi: 10.1158/1078-0432.CCR-22-2994.
PMID: 36789526